Overview
- The International Tennis Integrity Agency confirmed Monday that Arcuschin will serve a 20-month ban that keeps him out of competition, training and events until October 2027.
- A sample from the ITF M15 event in Lima in December 2025 showed a metabolite of estanozolol, an anabolic agent that is prohibited under anti-doping rules.
- Arcuschin has been under a mandatory provisional suspension since February 16, 2026, which bars him from playing, training and attending tennis activities while the case proceeded.
- At an August 11 hearing the tribunal found the violation likely unintentional after reviewing medical records that showed a sports doctor prescribed a 30-day compounded, unlabeled treatment that contained estanozolol and clomifene, and the panel reduced his degree of fault because of his age and recent injury and surgery history.
- The sanction removes a low-ranked 19-year-old (around ATP No. 1940) from the pro circuit during key development years and highlights the risk that unlabeled compounded medications pose to athletes, who remain strictly liable for any banned substance they ingest.